Exhibit 99.1
|
NEWS RELEASE |
CONTACTS:
Amin Khalifa, Chief Financial Officer
IRIS International, Inc.
818-527-7323
Amin Khalifa, Chief Financial Officer
IRIS International, Inc.
818-527-7323
-or-
Lynn Pieper, Westwicke Partners
415-202-5678
lynn.pieper@westwicke.com
415-202-5678
lynn.pieper@westwicke.com
IRIS INTERNATIONAL ANNOUNCES THIRD QUARTER 2011
REVENUE AND FINANCIAL RESULTS
REVENUE AND FINANCIAL RESULTS
| • | Record revenue of $28.1 million; 9% growth over Q3 2010 |
||
| • | Gross margin of 50% in Q3 2011; Excluding Arista, gross margin of 52% |
||
| • | Restructured Personalized Medicine Division by downsizing and consolidating
Arista Molecular’s operations into Iris Molecular Diagnostics |
||
| • | GAAP net loss per share of ($0.24); Non-GAAP diluted EPS was $0.05 per share
excluding $7.6 million of one-time restructuring charges and write-downs of related
assets |
CHATSWORTH, Calif., November 3, 2011 — IRIS International, Inc. (NASDAQ: IRIS), a leading
manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high
value personalized diagnostics testing services through its CLIA certified molecular diagnostics
laboratory, today announced financial results for the third quarter ended September 30, 2011.
Third Quarter 2011 Performance Highlights
| • | Achieved revenue of $28.1 million for the third quarter ended September 30, 2011,
representing 9% growth over Q3 2010. |
| • | Increased Iris Diagnostics Division (IDD) sales by 10% to $24.7 million as compared to
$22.4 million in the prior year period. |
| • | Realized gross margin of 50% for the third quarter 2011 compared to 51% in the prior
year period. Excluding the impact from Arista in both periods, consolidated gross margin
was 52%. |
| • | Received 510(k) clearance from the FDA in September 2011 and CE Mark approval in October
2011 for its NADiA® ProsVue™ prognostic prostate cancer test. |
| • | NADiA ProsVue slope is indicated for use as a prognostic marker in
conjunction with clinical evaluation as an aid in identifying those patients at
reduced risk for recurrence of prostate cancer for the eight year period following
prostatectomy. A ProsVue slope of less than 2.0 pg/ml per month in the first year
following radical prostatectomy was highly associated with no evidence of disease
over the long term follow up. |
| • | NADiA ProsVue is expected to reduce unnecessary treatment of certain
post-prostatectomy men thus reducing the morbidity and costs associated with
adjuvant treatment such as radiation therapy. |
| • | Completed restructuring of its Personalized Medicine division by downsizing and
consolidating Arista Molecular’s operations into Iris Molecular Diagnostics. Consolidation
enables significant cost reductions and enhanced profitability. |
| • | One-time restructuring expense of $1.8 million and write-downs of related
assets of $5.8 million taken in 3Q 2011. |
| • | Arista has retained all licenses and high-complexity CLIA laboratory
capabilities, as well as the necessary personnel to perform NADiA ProsVue during the
early stages of product introduction. Non-proprietary testing services have been
discontinued. |
| • | Reported net loss for Q3 2011 of $4.3 million, versus net income of $0.9 million in Q3
2010. Net loss per share was ($0.24) in Q3 2011 versus diluted EPS of $0.05 in Q3 2010.
Excluding charges related to the restructuring of Arista that are one time in nature,
non-GAAP net income for Q3 2011 was $935,000 and non-GAAP diluted EPS was $0.05 per share,
in spite of an approximate $0.7 million increase in R&D spending to fund new platforms. |
“We are pleased to announce our third quarter results with record revenue reflecting strong growth
in our diagnostics business. The increase in instrument sales was primarily driven by strong
international demand, with consumable sales showing
double-digit growth driven by our large installed base,” stated César M. García, Chairman,
President and Chief Executive Officer of IRIS International.
“Additionally in the quarter, we restructured the Personalized Medicine business which we believe
will result in significant expense reductions and enhanced profitability in future periods. I am
particularly pleased that we also announced the FDA clearance and CE Mark approval of NADiA
ProsVue. We look forward to our initial launch in 2012 and long-term commercial success of
ProsVue,” Mr. García added.
“We continue to make significant progress on our 3GEMS urinalysis and hematology development
programs. In October, our 3GEMS Hematology program achieved another milestone by demonstrating the
integration of the complete blood count module with the imaging channel, triggering our second
milestone payment from our Japanese partner. In addition, our new automated FISH platform product
is on schedule to be launched in the first quarter of 2012 and is expected to reinvigorate growth
in our Iris Sample Processing Division. We are achieving significant milestones in our development
programs, which will further expand our product portfolio. These efforts coupled with our cost
reduction initiatives are expected to drive higher revenue and earnings growth starting in 2012.”
Third Quarter 2011 Financial Results
| • | Consolidated revenues of $28.1 million for Q3 2011 represented growth of 9% versus Q3
2010 consolidated revenues of $25.7 million. For the third quarter ended September 30,
2011, IDD sales increased 10% year over year to $24.7 million as compared to $22.4 million
in the prior year period, driven by strong growth in international instrument sales,
particularly in the Asia Pacific region. |
| • | IDD instrument sales of $7.1 million represented 5% growth over Q3 2010, driven
primarily by strong international sales in the quarter. IDD consumables and service revenue
of $17.5 million in Q3 2011 represented 13% growth over Q3 2010 and accounted for 62% of
sales in the quarter driven primarily by our larger domestic and international installed
base. |
| • | Revenue at the Iris Sample Processing Division increased 1% to $3.4 million for Q3 2011,
when compared with revenue of $3.3 million in Q3 2010. |
Consolidated gross margin was 50% for the third quarter 2011 versus 51% reported for the prior
period. Excluding the impact from the Arista segment, gross margin was 52% in both periods. IDD
instrument gross margin improved to 37% for Q3 2011 versus 35% in Q3 2010. The increase was
primarily driven by efficiency improvements related to higher production volume of iChemVELOCITY
and an integrated iRICELL workstation, slightly offset by regional mix with strong international
instrument sales in Q3 2011. IDD consumables and service gross margin was 57% for Q3 2011, as
compared to 59% in the year ago period, the decrease primarily resulting from higher costs of
Japanese sourced chemistry strips due to the appreciation of the Yen versus a year ago and an
increase in service personnel to support our increasing installed base of instruments. Gross margin
for the Sample Processing segment was 58% for Q3 2011 versus 54% in the prior year quarter. The
increase was primarily due to favorable product mix.
The net loss for Q3 2011 was $4.3 million, versus net income of $0.9 million in Q3 2010. Excluding
one-time impairment and restructuring charges in Q3 2011, non-GAAP net income was $935,000. The
effective tax rate for the third quarter was 42% compared with 41% for the third quarter of 2010.
The Company’s balance sheet remains strong with cash of $19 million and no debt at September 30,
2011.
2011 Company Outlook
The company is narrowing the full year 2011 revenue guidance range to $117 — $120 million from $117
- $123 million, representing 9-11% growth over 2010. The company is maintaining non-GAAP EPS
guidance $0.21 — $0.23, which excludes one-time restructuring and asset impairment charges taken in
the third quarter of 2011, but reflects cost reductions in the fourth quarter as a result of the
restructuring efforts.
Conference Call
IRIS International will host a conference call today at 4:30 p.m. Eastern time, 1:30 p.m. Pacific
time. To participate, dial 1-877-870-9220 approximately 10 minutes before the conference call is
scheduled to begin. Hold for the operator and reference the IRIS International conference call.
International callers should dial 973-638-3437. The conference call may also be accessed by means
of a live audio webcast on our website at http://proiris.com. The conference web cast will be
archived and available for replay for 30 days from the date of the broadcast.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that
analyze particles and living cell forms and structures, or morphology of a variety of body fluids.
The Company’s products leverage its strengths in flow imaging technology, particle recognition and
automation to bring efficiency to hospital and commercial laboratories. The initial applications
for its technology have been in the urinalysis market and the Company is the leading worldwide
provider of automated urine microscopy and chemistry systems, with an installed base of more than
3,400 systems in more than 50 countries. The Company is expanding its core imaging and morphology
expertise into related markets, including applications in hematology and body fluids. In addition,
the Company’s personalized medicine group has a high complexity CLIA-certified laboratory for the
further development and commercialization of the Company’s NADiA ultra-sensitive nucleic acid
detection immunoassay platform, with applications in oncology and infectious disease. For more
information, please visit www.proiris.com.
Safe Harbor Provision
This press release contains forward-looking statements made in reliance upon the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, the Company’s views on future financial performance, market
growth, capital requirements, regulatory developments, new product introductions and acquisitions,
and are generally identified by phrases such as “thinks,” “anticipates,” “believes,” “estimates,”
“expects,” “intends,” ,“plans,” and similar words. Forward-looking statements are not guarantees of
future performance and are inherently subject to uncertainties and other factors which could cause
actual results to differ materially from the forward-looking statement. These statements are based
upon, among other things, assumptions made by, and information currently available to, management,
including management’s own knowledge and assessment of the Company’s industry, R&D initiatives,
competition and capital requirements. Other factors and uncertainties that could affect the
Company’s forward-looking statements include, among other things, the following: identification of
feasible new product initiatives, management of R&D efforts and the resulting successful
development of new products and product platforms; obtaining regulatory approvals for new and
enhanced products; acceptance by customers of the Company’s products; integration of acquired
businesses; substantial expansion of international sales; reliance on key suppliers; the potential
need for changes in long-term strategy in response to future developments; future advances in
diagnostic testing methods and procedures; potential changes in government regulations and
healthcare policies, both of which could adversely affect the economics of the diagnostic testing
procedures automated by the Company’s products; rapid technological change in the microelectronics
and software industries; and competitive factors, including pricing pressures and the introduction
by others of new products with similar or better functionality than our products. These and other
risks are more fully described in the Company’s filings with the Securities and Exchange
Commission, including the Company’s most recently filed Annual Report on Form 10-K and Quarterly
Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of
important factors that could cause actual results to differ materially from those in the
forward-looking statements. The financial results
presented in this press release are subject to change pending the filing of the Company’s Quarterly
Report on Form 10-Q for the period ended September 30, 2011. The Company undertakes no obligation
to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Non-GAAP Financial Measures
“GAAP” refers to financial information presented in accordance with generally accepted accounting
principles in the United States.
To supplement the condensed consolidated financial statements and discussion presented on a GAAP
basis, this press release includes non-GAAP financial measures with respect to the three month and
nine month periods ended September 30, 2011. Management uses non-GAAP financial measures because
it believes the appropriate analysis of our profitability cannot be effectively considered while
incorporating the effect of unusual items and charges that have not been experienced consistently
in prior periods. Also, management believes these non-GAAP measures facilitate the comparison of
our historical results to our competitors. The Company is reporting herein the following non-GAAP
financial measures: “adjusted net income,” and “adjusted diluted earnings per share.” These
non-GAAP financial measures are not in accordance with or an alternative to GAAP.
Adjusted net income excludes items which are considered unusual and the related incremental tax
effect of these items. Adjusted diluted earnings per share excludes the effect of the same items
described above from diluted earnings per share. Reconciliations of net income (loss), the GAAP
measure most directly comparable to adjusted net income, and diluted earnings (loss) per share, the
GAAP measure most directly comparable to adjusted diluted earnings per share, are provided on the
attached schedule.
The presentation of historical non-GAAP financial measures is not meant to be considered in
isolation from or as a substitute for results prepared in accordance with GAAP. We use these
non-GAAP measures to supplement net earnings and other corresponding measures on a basis prepared
in conformance with GAAP. These non-GAAP financial measures reflect additional ways of viewing
aspects of our operations that when viewed with our GAAP results provide a more complete
understanding of factors and trends affecting our business. However, investors should understand
that the excluded items are actual expenses that may impact the cash available to us for other
uses. We strongly encourage investors to consider both net earnings (loss) and cash flows
determined under GAAP as compared to the non-GAAP measures presented and to perform their own
analysis, as appropriate.
Reconciling Items to Non-GAAP Financial Measures
The non-GAAP measures described above exclude the following items:
| a) | Arista and IDD restructuring related costs — For the three and nine month periods
ended September 30, 2011, we recorded restructuring related expenses of $1.8 million. |
| b) | Arista impairment charge — For the three and nine month periods ended September 30,
2011, we recorded an impairment charge of $5.8 million related to the Arista restructuring. |
(TABLES FOLLOW)
IRIS INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
IRIS INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
| September 30 | December 31, | |||||||
| 2011 | 2010 | |||||||
| (unaudited) | ||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 18,858 | $ | 25,531 | ||||
Accounts receivable, net |
23,264 | 20,733 | ||||||
Inventories |
13,252 | 10,310 | ||||||
Prepaid expenses and other current assets |
1,487 | 1,661 | ||||||
Investment in sales-type leases, current portion |
3,999 | 3,578 | ||||||
Deferred tax asset |
4,395 | 3,135 | ||||||
Total current assets |
65,255 | 64,948 | ||||||
Property and equipment, net |
13,871 | 12,035 | ||||||
Goodwill |
2,451 | 3,957 | ||||||
Intangible assets, net |
6,097 | 9,345 | ||||||
Software development costs, net |
2,407 | 2,637 | ||||||
Deferred tax asset |
2,495 | 2,615 | ||||||
Investment in sales-type leases, non-current portion |
11,268 | 10,002 | ||||||
Other assets |
1,262 | 1,070 | ||||||
Total assets |
$ | 105,106 | $ | 106,609 | ||||
Liabilities and Stockholders’ Equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 5,764 | $ | 5,795 | ||||
Accrued expenses |
8,476 | 7,513 | ||||||
Deferred service contract revenue, current portion |
3,849 | 3,205 | ||||||
Total current liabilities |
18,089 | 16,513 | ||||||
Deferred service contract revenue, non-current portion |
47 | 71 | ||||||
Other long term liabilities |
55 | 1,374 | ||||||
Total liabilities |
18,191 | 17,958 | ||||||
Commitments and contingencies |
||||||||
Stockholders’ equity: |
||||||||
Common stock |
179 | 178 | ||||||
Preferred Stock |
— | — | ||||||
Additional paid-in capital |
92,354 | 89,703 | ||||||
Other comprehensive income |
(156 | ) | 140 | |||||
Accumulated deficit |
(5,462 | ) | (1,370 | ) | ||||
Total stockholders’ equity |
86,915 | 88,651 | ||||||
Total liabilities and stockholders’ equity |
$ | 105,106 | $ | 106,609 | ||||
(More)
IRIS INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited — in thousands, except per share data)
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited — in thousands, except per share data)
| For the three months | For the nine months | |||||||||||||||
| ended September 30, | ended September 30, | |||||||||||||||
| 2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenues |
||||||||||||||||
IDD instruments |
$ | 7,147 | $ | 6,806 | $ | 22,772 | $ | 22,107 | ||||||||
IDD consumables and service |
17,545 | 15,558 | 51,577 | 45,274 | ||||||||||||
Sample processing instruments and supplies |
3,358 | 3,335 | 10,638 | 10,986 | ||||||||||||
Personalized medicine |
46 | 27 | 213 | 27 | ||||||||||||
Total revenues |
28,096 | 25,726 | 85,200 | 78,394 | ||||||||||||
Cost of Goods Sold |
||||||||||||||||
IDD instruments |
4,474 | 4,447 | 13,836 | 14,194 | ||||||||||||
IDD consumable and service |
7,492 | 6,425 | 22,060 | 18,168 | ||||||||||||
Sample processing instruments and supplies |
1,410 | 1,521 | 4,761 | 4,950 | ||||||||||||
Personalized medicine |
572 | 174 | 1,636 | 174 | ||||||||||||
Total cost of goods sold |
13,948 | 12,567 | 42,293 | 37,486 | ||||||||||||
Gross profit |
14,148 | 13,159 | 42,907 | 40,908 | ||||||||||||
Marketing and selling |
5,635 | 4,956 | 17,590 | 14,152 | ||||||||||||
General and administrative |
4,220 | 4,202 | 14,838 | 12,562 | ||||||||||||
Research and development, net |
4,275 | 3,605 | 12,414 | 11,138 | ||||||||||||
Impairment of assets |
5,829 | — | 5,829 | — | ||||||||||||
Restructuring expenses |
1,770 | — | 1,770 | — | ||||||||||||
Gain on revaluation of contingent consideration |
— | — | (1,225 | ) | — | |||||||||||
Total operating expenses |
21,729 | 12,763 | 51,216 | 37,852 | ||||||||||||
Operating income (loss) |
(7,581 | ) | 396 | (8,309 | ) | 3,056 | ||||||||||
Other income (expense): |
||||||||||||||||
Interest income |
278 | 328 | 826 | 844 | ||||||||||||
Interest expense |
(2 | ) | (2 | ) | (8 | ) | (7 | ) | ||||||||
Other income (expense) |
(16 | ) | 856 | 397 | 183 | |||||||||||
Income before provision for income taxes |
(7,321 | ) | 1,578 | (7,094 | ) | 4,076 | ||||||||||
Provision for income taxes |
(3,051 | ) | 654 | (3,003 | ) | 1,486 | ||||||||||
Net income (loss) |
$ | (4,270 | ) | $ | 924 | $ | (4,091 | ) | $ | 2,590 | ||||||
Net income (loss) per share — basic |
$ | (0.24 | ) | $ | 0.05 | $ | (0.23 | ) | $ | 0.14 | ||||||
Net income (loss) per share — diluted |
$ | (0.24 | ) | $ | 0.05 | $ | (0.23 | ) | $ | 0.14 | ||||||
Weighted average shares outstanding — basic |
17,845 | 17,978 | 17,793 | 17,947 | ||||||||||||
Weighted average shares outstanding — diluted |
17,845 | 18,044 | 17,793 | 18,056 | ||||||||||||
(More)
IRIS INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited — in thousands)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited — in thousands)
| For the nine months | ||||||||
| ended September 30, | ||||||||
| 2011 | 2010 | |||||||
Cash flows from operating activities: |
||||||||
Net income (loss) |
$ | (4,091 | ) | $ | 2,590 | |||
Adjustments to reconcile net income to net cash
provided by operating activities: |
||||||||
Loss on disposal of fixed assets |
21 | 5 | ||||||
Gain on foreign currency remeasurement |
(385 | ) | (105 | ) | ||||
Gain on revaluation of contingent consideration |
(1,225 | ) | — | |||||
Deferred taxes |
(1,419 | ) | 48 | |||||
Tax benefit from stock option exercises |
(66 | ) | (48 | ) | ||||
Depreciation and amortization |
4,027 | 3,084 | ||||||
Stock based compensation |
3,103 | 3,193 | ||||||
Impairment of assets |
5,829 | — | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(2,515 | ) | (736 | ) | ||||
Inventories |
(2,902 | ) | (1,469 | ) | ||||
Prepaid expenses and other current assets |
(16 | ) | (725 | ) | ||||
Investment in sales-type leases |
(1,677 | ) | (1,963 | ) | ||||
Accounts payable |
60 | 280 | ||||||
Accrued expenses |
879 | 1,737 | ||||||
Deferred service contract revenue |
639 | 845 | ||||||
Other liabilities |
(97 | ) | — | |||||
Net cash provided by operating activities |
165 | 6,736 | ||||||
Cash flows from investing activities: |
||||||||
Purchase of assets from European distributor |
— | (660 | ) | |||||
Acquisition of business |
— | (4,630 | ) | |||||
Refund on acquisition of business |
46 | — | ||||||
Acquisition of property and equipment |
(6,361 | ) | (2,029 | ) | ||||
Software development costs capitalized |
(419 | ) | (554 | ) | ||||
Net cash used in investing activities |
(6,734 | ) | (7,873 | ) | ||||
Cash flows from financing activities: |
||||||||
Issuance of common stock for cash |
71 | 31 | ||||||
Settlement on restricted stock tax withholding |
(243 | ) | (239 | ) | ||||
Repurchase of common stock |
— | (1,551 | ) | |||||
Tax benefit from stock option exercises |
66 | 48 | ||||||
Net cash used in financing activities |
(106 | ) | (1,711 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents |
2 | (295 | ) | |||||
Net decrease in cash and cash equivalents |
(6,673 | ) | (3,143 | ) | ||||
Cash and cash equivalents at beginning of period |
25,531 | 34,253 | ||||||
Cash and cash equivalents at end of period |
$ | 18,858 | $ | 31,110 | ||||
Supplemental schedule of non-cash financing activities: |
||||||||
During the nine months ended September 30, 2011, the
Company disposed of property and equipment with a
cost and accumulated
depreciation of $498 and $477, respectively. |
||||||||
Supplemental disclosure of cash flow information: |
||||||||
Cash paid for income taxes |
$ | 1,231 | $ | 2,066 | ||||
Cash paid for interest |
$ | 8 | $ | 7 | ||||
IRIS INTERNATIONAL, INC.
RECONCILIATION OF GAAP NET LOSS AND NET LOSS PER SHARE TO ADJUSTED
NET INCOME AND ADJUSTED DILUTED EARNINGS PER SHARE
(unaudited — in thousands, except per share data)
RECONCILIATION OF GAAP NET LOSS AND NET LOSS PER SHARE TO ADJUSTED
NET INCOME AND ADJUSTED DILUTED EARNINGS PER SHARE
(unaudited — in thousands, except per share data)
| For the three months | For the nine months | |||||||||||||||||||||||
| ended September 30, 2011 | ended September 30, 2011 | |||||||||||||||||||||||
| Pretax | After tax | Per diluted | Pretax | After tax | Per diluted | |||||||||||||||||||
| amount | amount(1)(2) | share | amount | amount | share | |||||||||||||||||||
GAAP net loss & net loss per share |
$ | (7,321 | ) | $ | (4,270 | ) | $ | (0.24 | ) | $ | (7,094 | ) | $ | (4,091 | ) | $ | (0.23 | ) | ||||||
Reconciling items: |
||||||||||||||||||||||||
Restructuring expenses |
1,770 | 1,080 | 0.06 | 1,770 | 1,080 | 0.06 | ||||||||||||||||||
Impairment charge (excluding Goodwill) |
4,369 | 2,665 | 0.15 | 4,369 | 2,665 | 0.15 | ||||||||||||||||||
Goodwill impairment (1) |
1,460 | 1,460 | 0.08 | 1,460 | 1,460 | 0.08 | ||||||||||||||||||
Adjusted net income & diluted EPS (3) |
$ | 278 | $ | 935 | $ | 0.05 | $ | 505 | $ | 1,114 | $ | 0.06 | ||||||||||||
| (1) | Goodwill is not tax affected |
|
| (2) | Reconciling items taxed at statutory rate of 39% |
|
| (3) | Amounts may not foot due to rounding. |
See accompanying Non-GAAP Financial Measures section for description of Non-GAAP adjustments.
# # #